AstraZeneca is a large pharma headquartered in UK. Over the past three years, AstraZeneca has been involved in 40 licensing and acquisition transactions, with a primary focus on Small Molecules (20 deals). The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
11
Active Trials
50
Top Modality
Small Molecules
Focus Area
Solid Tumors
Licensing, acquisition, and partnership transactions involving AstraZeneca in the past 12 months.
| Asset |
|---|
| Partner |
|---|
| Modality |
|---|
| Phase |
|---|
| Type |
|---|
| Date |
|---|
| Lynparza | Merck | Small Molecules | Approved | co development | Jul 20, 2026 |
| Next-generation cardiometabolic therapies | CSPC | Small Molecules | Unknown | option | Jul 18, 2026 |
| Preclinical molecules for two renal disease targets | CSPC Pharmaceutical Group | Small Molecules | Preclinical | option | Jul 18, 2026 |
| preclinical renal disease molecules | CSPC Pharmaceutical Group | Other | Preclinical | option | Jul 15, 2026 |
| Zegfrovy | Dizal Pharmaceutical | Small Molecules | Approved | license | Jul 14, 2026 |
| Obesity/chronic disease program | CSPC Pharmaceutical | Other | Unknown | collaboration | Jul 12, 2026 |
| TQC3721 | Sino Biopharmaceutical | Small Molecules | Phase 2 | license | Jul 8, 2026 |
| kidney drug discovery program | CSPC | Other | Discovery | collaboration | Jul 6, 2026 |
| kidney disease drug candidates | CSPC | Other | Discovery | collaboration | Jul 4, 2026 |
| kidney drug discovery program | CSPC | Other | Discovery | collaboration | Jul 4, 2026 |
Showing 10 of 19 recent transactions. Upgrade to Pro for full deal history with financials.
Therapeutic areas and modalities where AstraZeneca is most active based on deal history and clinical trial data.
Key indicators of AstraZeneca's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Acquisition Appetite
Strategic Priorities
AstraZeneca has 50 active clinical trials across 6 development phases.
20
Unknown
5
Phase 4
1
Not Applicable
12
Phase 1
9
Phase 2
3
Phase 3
Use Solidus to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
AstraZeneca is a large pharma company based in UK that has been actively engaged in licensing transactions across the biopharma landscape. With 40 deals over the past three years, AstraZeneca ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for AstraZeneca include Solid Tumors (14 deals and trials), Oncology (13 deals and trials), Autoimmune (12 deals and trials), and Mega Deals (11 deals and trials). In terms of modality, AstraZeneca has shown particular interest in small molecules, other, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for AstraZeneca and 850+ other biopharma companies. Use our Solidus to benchmark your asset against AstraZeneca's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.
© 2026 Ambrosia Ventures. All rights reserved.
Benchmarks powered by 1,600+ real biopharma licensing deals